ZNF521
ZNF521 (Zinc finger protein 521) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver, a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Pancreatic ductal adenocarcinoma, Oesophageal cancer, Cervical cancer and 5 more.
Overview
Transcription factor that can both act as an activator or a repressor depending on the context. Involved in BMP signalling and in the regulation of the immature compartment of the haematopoietic system. Associates with SMADs in response to BMP2 leading to activate transcription of BMP target genes.
Open Targets scores its association with cancer at 0.69 (direct and indirect evidence; datatypes literature 0.91, genetic association 0.24, somatic mutation 0.87). IntOGen calls it a driver in 9 cohorts (5 activating, 4 loss-of-function), covering Cervical Adenocarcinoma, Cutaneous Squamous Cell Carcinoma, Oesophageal Adenocarcinoma, Hepatocellular Carcinoma, Lung Squamous Cell Carcinoma, Nasopharyngeal Carcinoma and others.
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · ZNF521 (Zinc finger protein 521) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver, a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Pancreatic ductal adenocarcinoma, Oesophageal cancer, Cervical cancer and 5 more.
- 1 · What it is
ZNF521 (Zinc finger protein 521) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver, a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Pancreatic ductal adenocarcinoma, Oesophageal cancer, Cervical cancer and 5 more.
- 2 · What goes wrong in cancer
Transcription factor that can both act as an activator or a repressor depending on the context. Involved in BMP signalling and in the regulation of the immature compartment of the haematopoietic system.
- 3 · How drugs use it
No product in this corpus aims at ZNF521 yet. Transcription factors have no pocket to plug, so drugs either degrade them or block the partner protein they need to dock on DNA.
External identifiers
Sources: HGNC HGNC:24605 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q96K83 (protein name, function text, keywords and locations (REST API)); Open Targets ENSG00000198795 (association with cancer (MONDO_0004992) 0.69; per-cancer scores at or above 0.5: oesophageal cancer 0.51, skin cancer 0.55, breast cancer 0.54, lung cancer 0.56, biliary tract cancer 0.50 (GraphQL API, CC0)); IntOGen ZNF521 (driver in 9 cohorts (Act 5, LoF 4); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Biology
Transcription factor that can both act as an activator or a repressor depending on the context. Involved in BMP signalling and in the regulation of the immature compartment of the haematopoietic system. Associates with SMADs in response to BMP2 leading to activate transcription of BMP target genes. Acts as a transcriptional repressor via its interaction with EBF1, a transcription factor involved specification of B-cell lineage; this interaction preventing EBF1 to bind DNA and activate target genes. Location: Nucleus (UniProt). Locus 18q11.2 (HGNC).
- Pancreatic ductal adenocarcinoma: IntOGen driver in 2 cohorts (PAAD, PANCREAS)
- Oesophageal cancer: Open Targets association 0.51 with oesophageal cancer (MONDO_0007576); IntOGen driver in 1 cohort (ESCA)
- Cervical cancer: IntOGen driver in 1 cohort (CEAD)
- Hepatocellular carcinoma: IntOGen driver in 1 cohort (HCC)
- Nasopharyngeal carcinoma: IntOGen driver in 1 cohort (NPC)
- Ovarian cancer: IntOGen driver in 1 cohort (OVT)
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: IntOGen calls it an activating (Act) driver in 5 cohorts; IntOGen calls it a loss-of-function (LoF) driver in 4 cohorts; UniProt disease notes describe a translocation or gene fusion involving the gene. Evidence tier "cohort-driver" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
Latest papers
topQuery for this target: (TITLE:"ZNF521" OR ABSTRACT:"ZNF521" OR TITLE:"zinc finger protein 521" OR ABSTRACT:"zinc finger protein 521" OR TITLE:"Zinc finger protein 521" OR ABSTRACT:"Zinc finger protein 521" OR TITLE:"Evi3" OR ABSTRACT:"Evi3") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about ZNF521, not a curated reading list.
Similar pages
not linked directly; found by shared links- TargetFAT1
Shares Nasopharyngeal carcinoma, Lung cancer (all types), Oesophageal cancer, Cervical cancer.
- TargetARID2
Shares Nasopharyngeal carcinoma, Skin cancer (all types), Oesophageal cancer, Hepatocellular carcinoma.
- TargetNUTM1
Shares Lung cancer (all types), Skin cancer (all types), Oesophageal cancer, IntOGen.
- TargetKAT6A
Shares Lung cancer (all types), Skin cancer (all types), Oesophageal cancer, IntOGen.
- TargetCLTCL1
Shares Lung cancer (all types), Skin cancer (all types), Hepatocellular carcinoma, IntOGen.
- TargetFCRL4
Shares Lung cancer (all types), Skin cancer (all types), IntOGen, Pancreatic ductal adenocarcinoma.
- TargetHNF1A
Shares Lung cancer (all types), Skin cancer (all types), Hepatocellular carcinoma, IntOGen.
- TargetLRP1B
Shares Lung cancer (all types), Skin cancer (all types), Oesophageal cancer, IntOGen.